|
|
Prepublished online as a Blood First Edition Paper on May 13, 2002; DOI 10.1182/blood-2002-02-0390.
Submitted February 8, 2002
Accepted March 28, 2002
c-myc Proto-oncogene Expression in Hemophilic Synovitis: In vitro studies of the effects of iron and ceramide
Fei-Qiu Wen, Adnan A Jabbar, Yi-Xin Chen, Tamara Kazarian, Dharmesh A Patel, and Leonard A Valentino*
* Corresponding author; email: lvalentino{at}rush.edu.
Hemophilia is a rare congenital bleeding disorder that is due to the deficiency of blood coagulation factors VIII or IX. Recurrent musculoskeletal bleeding is common and bleeding into joints results in a chronic inflammatory condition termed hemophilic synovitis. This destructive process is characterized by hemosiderin deposition in the superficial and deeper layers of the synovial membrane as well as a proliferation of synovial fibroblasts and vascular cells. The hyperplastic synovium and neovascular changes are reminiscent of the histopathological appearance observed in malignant tissues. Indeed, the benign hyperplastic synovium in hemophilia patients displays similar invasive and destructive behaviors suggesting the possibility of analogous disturbances in growth control and locally invasive mechanisms. Iron plays a role in malignant cell growth, local invasion and tumor progression, possibly due to changes in the expression of the proto-oncogene, c-myc. We hypothesized that iron plays a similar role in hemophilic synovitis. To explore this hypothesis, we investigated the in vitro effects of iron on the proliferation of a primary, human synovial fibroblast cell (HSFC) line and the involvement of c-myc in this process. We also examined the role of ceramide, a sphingolipid capable of inducing apoptosis in this model system. HSFC proliferation was increased in a dose-dependent fashion and c-myc expression was enhanced by ferric citrate compared to sodium citrate control. Ceramide prevented both the iron-induced increases in HSFC proliferation and c-myc expression. These results indicate that iron probably plays a role in the proliferative changes observed in hemophilic joint disease and that aberrant expression of c-myc may underlie the iron effects. Furthermore, these results suggest that there may be a therapeutic role for ceramide in reversing these changes.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Roosendaal and F. Lafeber
Prophylactic Treatment for Prevention of Joint Disease in Hemophilia -- Cost versus Benefit
N. Engl. J. Med.,
August 9, 2007;
357(6):
603 - 605.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. McClain, N. Hakobyan, and L. A. Valentino
Vascularization of the Synovial Membrane in Hemophilic Synovitis.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
4018 - 4018.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hoffman, A. Harger, A. Lenkowski, U. Hedner, H. R. Roberts, and D. M. Monroe
Cutaneous wound healing is impaired in hemophilia B
Blood,
November 1, 2006;
108(9):
3053 - 3060.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Cruz, G. Porto, S. Morais, M. Campos, and M. de Sousa
HFE mutations in the pathobiology of hemophilic arthropathy
Blood,
April 15, 2005;
105(8):
3381 - 3382.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Valentino, N. Hakobyan, T. Kazarian, A. A. Jabbar, and K. J. Jabbar
Pathobiology of Hemophilic Synovitis II: Synovial Cell Proliferation.
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
3077 - 3077.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. Abshire
Are oncogenes responsible for hemophilic arthropathy?
Blood,
October 1, 2004;
104(7):
1911 - 1912.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Hakobyan, T. Kazarian, A. A. Jabbar, K. J. Jabbar, and L. A. Valentino
Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene
Blood,
October 1, 2004;
104(7):
2060 - 2064.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
